Cargando…

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the virus ent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passariello, Margherita, Gentile, Chiara, Ferrucci, Veronica, Sasso, Emanuele, Vetrei, Cinzia, Fusco, Giovanna, Viscardi, Maurizio, Brandi, Sergio, Cerino, Pellegrino, Zambrano, Nicola, Zollo, Massimo, De Lorenzo, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155001/ https://www.ncbi.nlm.nih.gov/pubmed/34040046 http://dx.doi.org/10.1038/s41598-021-90348-7

Ejemplares similares

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
por: Vetrei, Cinzia, et al.
Publicado: (2021)

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
por: Passariello, Margherita, et al.
Publicado: (2022)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis
por: Passariello, Margherita, et al.
Publicado: (2021)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
por: Vetrei, Cinzia, et al.
Publicado: (2021)

High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
por: Zambrano, Nicola, et al.
Publicado: (2022)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
por: Shah, Masaud, et al.
Publicado: (2020)

Protective effects elicited by cow milk fermented with L. Paracasei CBAL74 against SARS-CoV-2 infection in human enterocytes
por: Paparo, Lorella, et al.
Publicado: (2021)

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
por: Noy-Porat, Tal, et al.
Publicado: (2020)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19
por: Mi, Tianxiong, et al.
Publicado: (2020)

Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus
por: Parrington, Helen M., et al.
Publicado: (2023)

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization
por: Noy-Porat, Tal, et al.
Publicado: (2023)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine
por: Paparo, Lorella, et al.
Publicado: (2022)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Identification of Closed Linear Epitopes in S1-RBD and S2-HR1/2 of SARS-CoV-2 Spike Protein Able to Induce Neutralizing Abs
por: Watanabe, Yoshihiro, et al.
Publicado: (2023)

Human neutralizing mAbs against Middle East respiratory syndrome coronavirus (MERS-CoV)
Publicado: (2014)

Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb
por: Ahmed, Mohamed, et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron
por: Hao, Linhui, et al.
Publicado: (2023)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development
por: Gupta, Deepali, et al.
Publicado: (2022)

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
por: Sasso, Emanuele, et al.
Publicado: (2018)

Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro
por: Pan, Xiaoyan, et al.
Publicado: (2020)

The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy
por: Barcelona, Pablo F., et al.
Publicado: (2018)

Neutralizing mAbs against SFTS Virus Gn Protein Show Strong Therapeutic Effects in an SFTS Animal Model
por: Shimojima, Masayuki, et al.
Publicado: (2022)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
por: Otsubo, Ryota, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o9s4pfobmt0uv0qvobeqc2hls3